View
comments
While COVID-19 vaccine boosters are beginning to roll out for recipients of the Pfizer-BioNTech and Moderna vaccines, Americans who received the Johnson & Johnson (J&J) vaccine remain in limbo.
The one-dose vaccine's booster is set to be discussed by a U.S. Food and Drug Administration (FDA) advisory panel on Friday, but a report released on Thursday does not show optimism in the J&J shot.
The FDA did not show confidence in the need for the booster, because the data from the New Brunswick, New Jersey-based company was lacking, including limited evidence that a second shot would help against the highly contagious Delta variant.
While the advisory committee could still vote in favor of the booster on Friday, a failure to receive recommendation would be yet another of a long lists of setbacks the company has faced during its vaccine rollout.
An FDA advisory panel will discuss whether booster shots of the Johnson & Johnson COVID-19 vaccine (pictured) are needed for recipients six months after receiving the first shot. The agency did not show confidence in data submitted by the company in a recent report
The J&J vaccine's reputation has faltered in recent months. In April, its use was paused for two weeks after it was linked to six cases and one death of blood clotting